Overview

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Status:
RECRUITING
Trial end date:
2028-02-14
Target enrollment:
Participant gender:
Summary
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Phase:
PHASE1
Details
Lead Sponsor:
AstraZeneca